請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72526
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊台鴻 | |
dc.contributor.author | Jun-Wei Liu | en |
dc.contributor.author | 劉峻瑋 | zh_TW |
dc.date.accessioned | 2021-06-17T07:00:21Z | - |
dc.date.available | 2019-08-06 | |
dc.date.copyright | 2019-08-06 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-02 | |
dc.identifier.citation | 1. Staff, M.C., Definition of pulmonary fibrosis. 2014, Mayo Foundation for Medical Education and Research.: Mayo Foundation for Medical Education and Research.
2. Kalluri, R. and R.A. Weinberg, The basics of epithelial-mesenchymal transition. J Clin Invest, 2009. 119(6): p. 1420-8. 3. Ho, Y.Y., et al., Fibrosis--a lethal component of systemic sclerosis. Nat Rev Rheumatol, 2014. 10(7): p. 390-402. 4. Falke, L.L., et al., Diverse origins of the myofibroblast-implications for kidney fibrosis. Nat Rev Nephrol, 2015. 11(4): p. 233-44. 5. Zeisberg, M. and E.G. Neilson, Biomarkers for epithelial-mesenchymal transitions. J Clin Invest, 2009. 119(6): p. 1429-37. 6. Vincent-Salomon, A. and J.P. Thiery, Host microenvironment in breast cancer development: Epithelial–mesenchymal transition in breast cancer development. Breast Cancer Research, 2003. 5(2). 7. Janda, E., et al., Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol, 2002. 156(2): p. 299-313. 8. Douglas Hanahan, R.A., The Hallmarks of Cancer. Cell, 2000. Vol. 100, 57–70. 9. Thiery, J.P., Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer, 2002. 2(6): p. 442-54. 10. Iwano, M., et al., Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest, 2002. 110(3): p. 341-50. 11. Gu, L., et al., Effect of TGF-beta/Smad signaling pathway on lung myofibroblast differentiation. Acta Pharmacol Sin, 2007. 28(3): p. 382-91. 12. Kendall, R.T. and C.A. Feghali-Bostwick, Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol, 2014. 5: p. 123. 13. McDonaldt, C.K.a.J.A., The Roles of the Myofibroblast in IdiopathicPulmonaryFibrosis. AmericanJournalofPathology, 1991. 14. Kai Zhang, M.D.R., David Gordon, and a.S.H. Phan, Myofibroblasts and Their Role in Lung Collagen Gene Expression during Pulmonary Fibrosis. American Journal of Pathology, 1994. 15. Kawai, T. and S. Akira, Innate immune recognition of viral infection. Nat Immunol, 2006. 7(2): p. 131-7. 16. Pohlers, D., et al., TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochim Biophys Acta, 2009. 1792(8): p. 746-56. 17. Martinez, F.J., et al., Idiopathic pulmonary fibrosis. Nat Rev Dis Primers, 2017. 3: p. 17074. 18. Lederer, D.J. and F.J. Martinez, Idiopathic Pulmonary Fibrosis. N Engl J Med, 2018. 378(19): p. 1811-1823. 19. King, T.E., A. Pardo, and M. Selman, Idiopathic pulmonary fibrosis. The Lancet, 2011. 378(9807): p. 1949-1961. 20. Kreuter, M., et al., Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. The Lancet Respiratory Medicine, 2016. 4(5): p. 381-389. 21. Chen, L., S. Li, and W. Li, LOX/LOXL in pulmonary fibrosis: potential therapeutic targets. J Drug Target, 2019. 27(7): p. 790-796. 22. Zhang, Y., et al., P120-catenin regulates pulmonary fibrosis and TGF-beta induced lung fibroblast differentiation. Life Sci, 2019. 230: p. 35-44. 23. Roach, K.M., et al., A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis. Sci Rep, 2018. 8(1): p. 342. 24. Hughes, G., et al., Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. J Clin Med, 2016. 5(9). 25. National Institute for Health and Care Excellence. Pirfenidone for treating idiopathic pulmonary fibrosis. In NICE Technology Appraisal Guidance (TA282), N.I.f.H.a.C.E. Manchester, Editor. 2013: UK. 26. Klatzmann, D. and A.K. Abbas, The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol, 2015. 15(5): p. 283-94. 27. Keiko Hisatomi1, H.M., Noriho Sakamoto1*, Yuji Ishimatsu1, Tomoyuki Kakugawa1, Shintaro Hara1, Hanako Fujita1, Seiko Nakamichi3, Hisashi Oku4, Yoshishige Urata5, Hiroshi Kubota6, Kazuhiro Nagata6 and Shigeru Kohno1 and Pirfenidone inhibits TGF-β1-induced over- expression of collagen type I and heat shock protein 47 in A549 cells. Hisatomi et al. BMC Pulmonary Medicine 2012. 28. Risto PIRINEN1, R.T., Markku TAMMI2, Pasi HIRVIKOSKI3, Jyrki J. PARKKINEN1, Risto JOHANSSON4, Jan BO ̈HM1, Sinikka HOLLME ́N5 and Veli-Matti KOSMA1*, PROGNOSTIC VALUE OF HYALURONAN EXPRESSION IN NON-SMALL-CELL LUNG CANCER: INCREASED STROMAL EXPRESSION INDICATES UNFAVORABLE OUTCOME IN PATIENTS WITH ADENOCARCINOMA. Int. J. Cancer, 2001. 95, 12–17. 29. Maarit A. Anttila, R.H.T., Markku I. Tammi, Kari J. Syrja ̈nen, Seppo V. Saarikoski, and Veli-Matti Kosma, High Levels of Stromal Hyaluronan Predict Poor Disease Outcome in Epithelial Ovarian Cancer. CANCER RESEARCH, 2000. 150 –155. 30. Morera, D.S., et al., Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets. Br J Cancer, 2017. 117(10): p. 1507-1517. 31. Jordan, A.R., et al., The Role of CD44 in Disease Pathophysiology and Targeted Treatment. Front Immunol, 2015. 6: p. 182. 32. Kazezian, Z., et al., Injectable hyaluronic acid down-regulates interferon signaling molecules, IGFBP3 and IFIT3 in the bovine intervertebral disc. Acta Biomater, 2017. 52: p. 118-129. 33. Liu, M.C., et al., Inhibition of chronic prostate inflammation by hyaluronic acid through an immortalized human prostate stromal cell line model. PLoS One, 2017. 12(5): p. e0178152. 34. Huang, T.W., et al., Hyaluronan antagonizes the differentiation effect of TGF-beta1 on nasal epithelial cells through down-regulation of TGF-beta type I receptor. Artif Cells Nanomed Biotechnol, 2018. 46(sup3): p. S254-S263. 35. Khor, E. and L.Y. Lim, Implantable applications of chitin and chitosan. Biomaterials, 2003. 24(13): p. 2339-2349. 36. Cooksley, C., et al., TLR response pathways in NuLi-1 cells and primary human nasal epithelial cells. Mol Immunol, 2015. 68(2 Pt B): p. 476-83. 37. Chen, C., et al., The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol, 2018. 11(1): p. 64. 38. Wang, L., et al., The Role of CD44 and Cancer Stem Cells. Methods Mol Biol, 2018. 1692: p. 31-42. 39. Bourguignon, L.Y., et al., Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem, 2002. 277(42): p. 39703-12. 40. Ito, T., et al., Hyaluronan regulates transforming growth factor-beta1 receptor compartmentalization. J Biol Chem, 2004. 279(24): p. 25326-32. 41. Molina, S.A., et al., Junctional abnormalities in human airway epithelial cells expressing F508del CFTR. Am J Physiol Lung Cell Mol Physiol, 2015. 309(5): p. L475-87. 42. Goueffic, Y., et al., Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. Cardiovasc Res, 2006. 72(2): p. 339-48. 43. Birgit Du«be a, H.J.L.k.a., Monique Aumailley b, Peter Prehm, Hyaluronan reduces migration and proliferation in CHO cells. Biochimica et Biophysica Acta, 2001. 283-289. 44. Risto PIRINEN, R.T., Markku TAMMI, Pasi HIRVIKOSKI, Jyrki J. PARKKINEN, Risto JOHANSSON, Jan BO ̈HM, Sinikka HOLLME ́N and Veli-Matti KOSMA, PROGNOSTIC VALUE OF HYALURONAN EXPRESSION IN NON-SMALL-CELL LUNG CANCER: INCREASED STROMAL EXPRESSION INDICATES UNFAVORABLE OUTCOME IN PATIENTS WITH ADENOCARCINOMA. Int. J. Cancer, 2001. 12-17. 45. Sironen, R.K., et al., Hyaluronan in human malignancies. Exp Cell Res, 2011. 317(4): p. 383-91. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72526 | - |
dc.description.abstract | 肺纖維化還是現今醫學難以解決的問題,其中以特發性纖維化最為代表,在先前的研究中,我們發現玻尿酸對於上呼吸道的上皮細胞,能透過抑制乙型轉化生長因子的訊號,來抑制上皮細胞間質轉化的功能,進而減緩纖維化。在本篇研究中,我們希望能夠複製玻尿酸在上呼吸道之特性到下呼吸道的上皮細胞,進而達到能抑制肺纖維化的作用。我們利用A549和Nuli-1這兩株細胞來做測試,但根據實驗結果顯示,玻尿酸在A549肺癌細胞上反而會助長上皮細胞間質轉化,而在Nuli-1玻尿酸能讓上皮細胞表現更好的上皮極性,但也無法抑制上皮細胞間質轉化。
另外一方面,纖維母細胞分化成肌纖維母細胞也是造成纖維化的一個原因,本研究我們同樣使用玻尿酸來測試鼻部纖維母細胞分化的情形。根據研究結果,我們發現玻尿酸無法阻止纖維母細胞分化成肌纖維母細胞,甚至單純加入玻尿酸會助長纖維母細胞的爬行速度,但我們發現玻尿酸可以抑制肌纖維母細胞所造成的過量細胞外基質。因此,本研究之結果,我們可以得知上下呼吸道上皮細胞對於玻尿酸的反應是不同的,以及玻尿酸能夠抑制過量細胞外基質產生。 | zh_TW |
dc.description.abstract | Inhibiting lung fibrosis is still an unmet need, and idiopathic lung fibrosis (IPF) is typical lung fibrosis. In previous reports, we knew that hyaluronan (HA) could antagonize the differentiation effect of TGF-ß1 on nasal epithelial cells through the downregulation of TGF-ß type I receptor. Therefore, in this study, we hope to replicate the effect of HA on upper respiratory epithelial cells to lower respiratory epithelial cells and attenuate lung fibrosis. However, we can’t have the same effect on A549, lung cancer epithelial cells; HA even enhances the epithelial-mesenchymal transition (EMT) on A549. Hyaluronan can evaluate the epithelial integrity but can not reduce the EMT on Nuli-1 either.
On the other hand, the differentiation of fibroblasts to myofibroblasts is another reason for fibrosis. In this study, we have observed that HA can not attenuate the myofibroblast differentiation, even the group with HA alone enhance the migration rate of nasal fibroblasts. However, we have found that HA can inhibit the excessive secretion of NFBs, which makes fibrosis worse. Consequently, we have found the effect of HA on upper respiratory and lower respiratory epithelial cells are different. Moreover, HA can inhibit the excessive secretion of myofibroblast through inhibiting TGF-b1 pathway. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:00:21Z (GMT). No. of bitstreams: 1 ntu-108-R06548011-1.pdf: 3306268 bytes, checksum: fc81f32a18a6793adc29a7db736e448f (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 ii Abstract iii CONTENT iv LIST OF FIGURES vii Chapter 1 Introduction 1 1.1 Two Resource to Fibrosis 1 1.1.1 Epithelial-Mesenchymal Transition 2 1.1.2 Myofibroblast differentiation 3 1.2 Idiopathic pulmonary fibrosis 4 1.3 Current treatments for Idiopathic Pulmonary fibrosis 5 1.4 Strategy: Hyaluronan and chitosan 6 Chapter 2 Materials and Methods 8 2.1.1 A549 8 2.1.2 Nuli-1 8 2.1.3 Primary Nasal Fibroblasts (NFBs) 9 2.2 Treatment in vivo 9 2.2.1 Hyaluronan medium for A549 9 2.2.2 Hyaluronan or chitosan medium for Nuli-1 10 2.2.3 Hyaluronan or chitosan medium for NFB 10 2.3 Western blot analysis 11 2.4 Measurements of transepithelial electrical resistance (TER) 12 2.5 Immunocytochemistry 12 2.6 Collagen assay 13 2.7 Wound Healing 14 2.8 Invasion Testing 15 Chapter 3 Result 16 3.1 Part A – Lung epithelial cells 16 3.1.1 The effect of hyaluronan on A549 16 3.1.2 The effect of hyaluronan on Nuli-1 16 3.1.3 The effect of chitosan on Nuli-1 17 3.1.4 Wound healing 18 3.1.5 Immunocytochemistry of Nuli-1 and TER 18 3.2 Part B- Nasal Fibroblast 18 3.2.1 NFB characterization 18 3.2.2 The effect of biomaterials on myofibroblast differentiation induced by TGF-b1 and TNF-alpha. 19 3.2.3 Collagen Assay 20 3.2.4 Invasion and migration assay 20 Chapter 4 Discussion and Conclusion 21 Chapter 5 Figure 24 Reference: 35 | |
dc.language.iso | en | |
dc.title | 生醫材料對於抑制下呼吸道表皮細胞以及上呼吸道間質細胞之纖維化 | zh_TW |
dc.title | The Effects of Biomaterials on Inhibiting Fibrosis of Lung Epithelial Cells and Nasal Fibroblasts | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 黃琮瑋 | |
dc.contributor.oralexamcommittee | 林宏殷,李玫樺 | |
dc.subject.keyword | 玻尿酸,肺上皮細胞,上皮細胞間質轉化,纖維母細胞,肌纖維母細胞分化, | zh_TW |
dc.subject.keyword | hyaluronan/hyaluronic acid,lung epithelial cell,epithelial-mesenchymal transition,fibroblast,myofibroblast differentiation, | en |
dc.relation.page | 38 | |
dc.identifier.doi | 10.6342/NTU201902304 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-02 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 3.23 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。